The latest report from data and analytics company, GlobalData, has revealed that the glaucoma market is expected to grow to $3.8 billion in 2026 as a result of the launch of pipeline products.
Administration of quadrivalent flu jabs should be on the agenda for the NHS as fourth flu strain, known as ‘Japanese flu’ is becoming most prevalent in Europe, according to data and analytics company, GlobalData.
Accord Healthcare, a generic pharmaceutical company, has opened a new facility in Fawdon, Newcastle, expanding its portfolio to four sites situated within the UK.
Spotting the signs and symptoms of various infectious diseases can mean the difference between life and death. According to research in the journal Epidemiology and Infection, public awareness campaigns are vital in stopping infections spreading
The Brexit Health Alliance (BHA) has urged for regulatory arrangements to be made as a matter of urgency to prevent any potential risk to public health as a result of Brexit.
Global innovator and provider of cold chain packaging systems for the pharma industry, Softbox, has acquired TP3 Global, which manufactures the ‘SilverSkin’ brand.
A new report released by the BioIndustry Association (BIA) and Informa Pharma Intelligence has revealed that the UK has the strongest research and development (R&D) pipeline in Europe.
The Access to Medicine Foundation has published an independent analysis of the efforts made by pharma companies to address the issue of drug resistant infections.
The collaboration between AstraZeneca and TissUse is progressing with the establishment of relevant microphysiological system (MPS) models based on TissUse’s multi-organ-chip technology, the companies announced.
In this online exclusive, Jessica Foreman, freelance writer who works within the life sciences sector, reveals her guide on how to ensure you are maximising value at each stage of product development
A new joint report from the Medicines Discovery Catapult and the UK BioIndustry Association (BIA), released today (Thursday 18 January) has revealed insights into the productivity of the UK’s drug discovery community.
A study of clinical trial professionals has revealed the top challenges and frustrations with current Randomization and Trial Supply Management/Interactive Response Technology (RTSM/IRT) systems as well as opportunities for improvement.
